VolitionRx Reports Over 95% Early-Stage Cancer Detection in Validation Study

VolitionRx Limited announced proof-of-concept data from a blinded validation cohort demonstrating over 95% sensitivity for stage I and II cancers with 95% specificity using its Capture-Seq liquid biopsy technology. The study, which included 81 subjects, showed detection rates of 94% for stage I and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%, highlighting the technology’s potential for early cancer detection.

Volition said Capture-Seq is designed to enrich and purify circulating tumor DNA for analysis and may support applications in multi-cancer early detection and minimal residual disease monitoring. The company noted the technology targets an estimated $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization.

The significance of these findings lies in the challenge of detecting cancer in its earliest stages, when treatment is most effective. Current screening methods often have limitations in sensitivity for early-stage disease or are invasive procedures that many patients avoid. A blood-based test with the reported accuracy could dramatically improve early detection rates across multiple cancer types.

Volition is a multi-national company focused on advancing the science of epigenetics and is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.

Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information about the company’s work, visit https://volition.com/.

The announcement was made through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. For more information about the distribution service, visit https://www.InvestorWire.com. The full press release containing these results can be viewed at https://ibn.fm/ktVDF.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VolitionRx Reports Over 95% Early-Stage Cancer Detection in Validation Study.

The post VolitionRx Reports Over 95% Early-Stage Cancer Detection in Validation Study appeared first on citybuzz.